Not exact matches
The NAPOLI - 1 (NAnoliPOsomaL
Irinotecan) Phase 3 study — a final confirmation of a drug's safety and effectiveness — was conducted among patients with metastatic pancreatic cancer who previously received gemcitibine, which has been the standard - of - care therapy
for such patients.
Previous research by Redinbo and others revealed that inhibiting Beta - glucuronidase helps reduce the GI toxicity associated with
irinotecan, suggesting that bacteria are responsible
for the drug's side effects.
Here's one example of how this information might be useful
for doctors and patients:
Irinotecan is a drug only indicated by the FDA
for use in colon cancer.
The introduction of nanocarriers as delivery vehicles
for common chemotherapy agents such as the drug
irinotecan, has led to improved survival of patients with this disease.
The investigators used the nanoparticle plus the iRGD to deliver
irinotecan in a robust animal model
for pancreatic cancer that closely mimics human disease.
Scientists leading the new study will also look
for biomarkers in patients that could help determine which of them are most likely to benefit from guadecitabine and
irinotecan.
In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show
for the first time that the experimental drug guadecitabine (SGI - 110) is safe in combination with the chemotherapy drug
irinotecan and may overcome resistance to
irinotecan in patients with metastatic colorectal cancer.
While thousands of agents based on camptothecin have been synthesized, and two of these analogs —
irinotecan and topotecan — have been approved
for treatment of many solid - tumor cancers, these compounds typically are highly toxic to healthy cells, and not all of them have proven effective as anticancer agents.
The new compound targets topoisomease I, an enzyme that is already exploited
for cancer chemotherapy by topotecan and
irinotecan.
Choy, H, Chakravarthy, A. Phase I trial of
Irinotecan and concurrent radiation therapy
for stage III non-small cell lung cancer.
Dr. Innocenti is a co-inventor of the FDA - approved UGT1A1 genetic test
for patients treated with
irinotecan.
One of Dr. Innocentis exemplary achievements is the elucidation of the genetic basis of severe neutropenia in cancer patients treated with
irinotecan, a poster child
for pharmacogenetic.
Ratain,
for example, got his start in the field studying
irinotecan, a drug used to fight colorectal cancer.
Weekly
irinotecan and concurrent radiation therapy
for stage III unresectable non-small cell lung cancer.
36) Gao K, Lockwood WW, Li J, Lam WL, Li G (2008) Genomic analyses identify gene candidates
for acquired
irinotecan resistance in melanoma cells.